Hypertensie High blood pressure
Conditions
Interventions
None listed
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Aged from 18 to 75 years old - A signed and dated informed consent form - A diagnosis of hypertension defined either as: o Use of antihypertensive drug (s) o Arterial hypertension: in untreated patients this must be confirmed by daytime ambulatory blood pressure monitoring (ABPM), or home blood pressure monitoring, with blood pressure higher or equal to 135 mmHg for systolic blood pressure and/or higher or equal to 85 mmHg for diastolic blood pressure. ;In order to be eligible to participate in the nested case control study, a subject must also meet the following criteria: - A conformed diagnosis of PA, PPGL or CS for case patients and PHT (exclusion of secondary forms) for their matched counterparts
Exclusion criteria
Exclusion criteria: potential subject who meets any of the following criteria will be excluded from participation in the prospective cohort is any of the following criteria will be present: - Any severe comorbid conditions that, according to the attending physician, could decrease the life expectancy to less than 3 years - Any active malignancy unrelated to adrenal disease or PPGL ;- Guardianship for incapacity;A potential control subject who meets any of the following criteria will be excluded from participation in the nested case controlled study in case of: - Existence of any other forms of secondary hypertension such as renal artery stenosis, renal disease, Munchausen*s syndrome - Drug-induced hypertension - Documented non-adherence to medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the diagnostic performance (sensitivity, specificity, positive and negative predictive value and diagnostic odds ratios) of omics to diagnose EHBP. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints are defined as following: - Occurrence of major adverse cardiovascular events (MACE) within 12 months after V1 defined as: death, myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) or need for them, cerebrovascular accident (CVA), hospitalization for acute decompensated heart failure. - Left ventricular (LV) hypertrophy, microalbuminuria, atrial fibrillation - Quality of life and 'psychomics': , RAND36, (quality of life), EQ5D (quality of life), HADS (anxiety and depression), CFQ (cognitive functioning) and MOCA (cognitive functioning) - costs (cost of evaluation, cost of misdiagnosis) - BP level on ABPM/HBPM, number of drugs, Defined Daily Dosages (DDD) (http://www.whocc.no/ddd/definition_and_general_considera/) | — |
Countries
Netherlands
Outcome results
None listed